LEVEMIR FLEXPEN
LOE ApproachingBLASUBCUTANEOUSINJECTABLE
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Levemir FlexPen is a long-acting basal insulin analog (insulin detemir) administered via subcutaneous injection for Type 1 and Type 2 diabetes management. It provides steady, peakless insulin coverage over 24 hours, reducing fasting glucose and overall glycemic variability. The FlexPen delivery device offers convenience and dose flexibility compared to vial-and-syringe administration.
$1.0BPart D
LOE ApproachingMature asset with significant Part D penetration (1.4M claims) facing biosimilar and competitor pressure; brand teams are likely focused on defensive positioning and lifecycle extension.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
$1.0B Medicare spend — this is a commercially significant brand
Worked on LEVEMIR FLEXPEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.